PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The presence of PEDs in nAMD, CSR and iPCV can present a diagnostic challenge in the elderly
population; despite detailed diagnostic testing to differentiate these three conditions,
misdiagnosis and mistreatment still occurs. One potential way of differentiating these three
conditions might be to compare cytokine profiles in nAMD versus CSR versus iPCV. This
information may be useful in creating a diagnostic aqueous cytokine and hormone profile to
differentiate between nAMD, CSR and iPCV.
The primary goal of this study is to compare baseline aqueous cytokine and cortisol levels
between nAMD, CSR, and iPCV patients and age-matched cataract controls. The secondary
objective is to assess intra-group changes in visual and anatomical outcomes in nAMD, CSR and
iPCV patients with PED treated with aflibercept and correlate these changes to baseline
cytokines.